WebNov 12, 2024 · An excellent example of this was shown in a prostate cancer mouse xenograft model, where CSNK2A1 siRNA was delivered via a nanoparticle delivery … WebJun 15, 2024 · CK2 α /CSNK2A1 is involved in cancer progr ess ion by phosphorylating various signaling molecules. Conside ring the ro le of CSNK2A1 in cance r pro gres sion and phosphorylation of SIRT6 and the ...
CSNK2A1 — Early Detection Research Network
WebJun 11, 2024 · Our results reveal that CSNK2A1-dependent HMGA2 phosphorylation may partially underlie cisplatin-resistance in cervical cancer, suggesting that HMGA2 phosphorylation may have potential as a predicative biomarker and therapeutic target to improve chemotherapeutic efficacy. Conflict of interests WebApr 30, 2024 · Additionally, a limitation of essentially all targeted anti-cancer therapies is the onset of treatment-induced acquired resistance (17,18). In response to pharmacologic inhibition of a key cancer driver, cancer cells can induce a complex array of responses that functionally compensate for target inhibition. camping les acacias beton bazoches
Defining the KRAS-regulated kinome in KRAS-mutant …
WebJun 11, 2024 · Our results reveal that CSNK2A1-dependent HMGA2 phosphorylation may partially underlie cisplatin-resistance in cervical cancer, suggesting that HMGA2 phosphorylation may have potential as … WebDec 13, 2024 · CSNK2A1 is an oncogene found overexpressed in several cancer types, including ovarian cancer, and is responsible for increased growth and cell survivability in the presence of chemotherapeutic agents.27,28 The protein encoded by CSNK2A1, CK2α, plays a major role in cell cycle regulation, cell-cell communication, DNA repair activation, … WebFor instance, CSNK2A1 promotes gastric cancer invasiveness via the PI3K-Akt-mTOR signal pathway; CSNK2A1 is a mediator of MEK/ERK inhibitor resistance in KRAS (G12C) mutant LC cells [52]; CSNK2A1 ... firthfields